NASDAQ:VCYT Veracyte (VCYT) Stock Price, News & Analysis $25.02 -0.23 (-0.91%) Closing price 07/28/2025 04:00 PM EasternExtended Trading$25.18 +0.16 (+0.66%) As of 04:52 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Veracyte Stock (NASDAQ:VCYT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Veracyte alerts:Sign Up Key Stats Today's Range$24.85▼$25.6050-Day Range$23.03▼$28.8152-Week Range$19.73▼$47.32Volume15.57 million shsAverage Volume1.06 million shsMarket Capitalization$1.96 billionP/E Ratio61.03Dividend YieldN/APrice Target$40.90Consensus RatingModerate Buy Company Overview Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA. Read More Veracyte Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks76th Percentile Overall ScoreVCYT MarketRank™: Veracyte scored higher than 76% of companies evaluated by MarketBeat, and ranked 261st out of 939 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingVeracyte has received a consensus rating of Moderate Buy. The company's average rating score is 2.70, and is based on 8 buy ratings, 1 hold rating, and 1 sell rating.Amount of Analyst CoverageVeracyte has only been the subject of 2 research reports in the past 90 days.Read more about Veracyte's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings Growth5.88% Earnings GrowthEarnings for Veracyte are expected to grow by 5.88% in the coming year, from $0.68 to $0.72 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Veracyte is 61.03, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 27.85.Price to Earnings Ratio vs. SectorThe P/E ratio of Veracyte is 61.03, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 28.26.Price to Book Value per Share RatioVeracyte has a P/B Ratio of 1.65. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Veracyte's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.69% of the float of Veracyte has been sold short.Short Interest Ratio / Days to CoverVeracyte has a short interest ratio ("days to cover") of 6.Change versus previous monthShort interest in Veracyte has recently increased by 8.59%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVeracyte does not currently pay a dividend.Dividend GrowthVeracyte does not have a long track record of dividend growth. Sustainability and ESG4.3 / 5Environmental Score-1.10 Percentage of Shares Shorted7.69% of the float of Veracyte has been sold short.Short Interest Ratio / Days to CoverVeracyte has a short interest ratio ("days to cover") of 6.Change versus previous monthShort interest in Veracyte has recently increased by 8.59%, indicating that investor sentiment is decreasing significantly. News and Social Media4.1 / 5News Sentiment1.29 News SentimentVeracyte has a news sentiment score of 1.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.08 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Veracyte this week, compared to 7 articles on an average week.Search Interest10 people have searched for VCYT on MarketBeat in the last 30 days. This is an increase of 900% compared to the previous 30 days.MarketBeat Follows5 people have added Veracyte to their MarketBeat watchlist in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Veracyte insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.40% of the stock of Veracyte is held by insiders.Read more about Veracyte's insider trading history. Receive VCYT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Veracyte and its competitors with MarketBeat's FREE daily newsletter. Email Address VCYT Stock News HeadlinesVeracyte (NASDAQ:VCYT) Shares Gap Up - What's Next?July 27 at 3:40 AM | americanbankingnews.comVeracyte (VCYT) Soars 7% on S&P SmallCap 600 InclusionJuly 26 at 12:31 PM | insidermonkey.comIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered a revolutionary AI breakthrough buried inside Tesla's labs. One that is helping AI escape from our computer screens and manifest itself here in the real world all while creating a 25,000% growth market explosion starting as early as October 23rd. | Brownstone Research (Ad)Veracyte to replace Triumph in S&P SmallCap 600 indexJuly 25, 2025 | msn.comBrokerages Set Veracyte, Inc. (NASDAQ:VCYT) Price Target at $40.90July 21, 2025 | americanbankingnews.comVeracyte Inc (VCYT) Stock Price Down 4.21% on Jul 18July 18, 2025 | gurufocus.comVeracyte to Release Second Quarter 2025 Financial Results on August 6, 2025July 17, 2025 | businesswire.comVeracyte Announces that Multiple Afirma GRID Studies Will Be Presented at ENDO 2025 - MorningstarJuly 10, 2025 | morningstar.comMSee More Headlines VCYT Stock Analysis - Frequently Asked Questions How have VCYT shares performed this year? Veracyte's stock was trading at $39.60 at the beginning of the year. Since then, VCYT shares have decreased by 36.8% and is now trading at $25.02. How were Veracyte's earnings last quarter? Veracyte, Inc. (NASDAQ:VCYT) announced its quarterly earnings results on Monday, February, 24th. The biotechnology company reported $0.36 EPS for the quarter, beating the consensus estimate of $0.29 by $0.07. The biotechnology company had revenue of $118.63 million for the quarter, compared to analysts' expectations of $110.73 million. Veracyte had a trailing twelve-month return on equity of 6.14% and a net margin of 7.13%. Read the conference call transcript. Does Veracyte have any subsidiaries? Veracyte subsidiaries include HalioDx Inc., Decipher Biosciences Inc., Allegro Diagnostics, Decipher Corp., Delight Merger Sub II LLC, Veracyte Global B.V., Veracyte International Corp., and Veracyte SAS. Who are Veracyte's major shareholders? Top institutional investors of Veracyte include Assenagon Asset Management S.A. (1.06%), AEGON ASSET MANAGEMENT UK Plc (0.39%), Aberdeen Group plc (0.23%) and Palisades Investment Partners LLC (0.21%). Insiders that own company stock include Rebecca Chambers, John Leite, Giulia C Kennedy, Bonnie H Anderson, Jonathan Wygant, Jonathan Wygant, Evan/ Fa Jones, John L Bishop, Jens Holstein, Muna Bhanji and Karin Eastham. View institutional ownership trends. How do I buy shares of Veracyte? Shares of VCYT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Veracyte own? Based on aggregate information from My MarketBeat watchlists, some other companies that Veracyte investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Netflix (NFLX), Broadcom (AVGO) and JPMorgan Chase & Co. (JPM). Company Calendar Last Earnings2/24/2025Today7/28/2025Next Earnings (Estimated)8/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED INSTRUMENTS Sub-IndustryHealthcare Current SymbolNASDAQ:VCYT CIK1384101 Webwww.veracyte.com Phone(650) 243-6300Fax650-243-6301Employees790Year Founded2006Price Target and Rating Average Price Target for Veracyte$40.90 High Price Target$50.00 Low Price Target$28.00 Potential Upside/Downside+63.5%Consensus RatingModerate Buy Rating Score (0-4)2.70 Research Coverage10 Analysts Profitability EPS (Trailing Twelve Months)$0.41 Trailing P/E Ratio61.03 Forward P/E Ratio36.79 P/E GrowthN/ANet Income$24.14 million Net Margins7.13% Pretax Margin7.57% Return on Equity6.14% Return on Assets5.60% Debt Debt-to-Equity RatioN/A Current Ratio5.10 Quick Ratio4.78 Sales & Book Value Annual Sales$445.76 million Price / Sales4.40 Cash Flow$1.03 per share Price / Cash Flow24.35 Book Value$15.17 per share Price / Book1.65Miscellaneous Outstanding Shares78,320,000Free Float77,219,000Market Cap$1.96 billion OptionableOptionable Beta2.07 Social Links Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report This page (NASDAQ:VCYT) was last updated on 7/29/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Veracyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Veracyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.